Pharmacy Times
JULY 7, 2022
People have been taking probiotics to support digestive health for centuries, but researchers in the pulmonary field have turned their attention toward how microbiome science can be used to support the lungs.
Pharmaceutical Technology
JULY 7, 2022
Brii Biosciences and TSB Therapeutics have commercially launched a long-acting neutralising antibody therapy combination, amubarvimab/romlusevimab, for Covid-19 in China. The two non-competing SARS-CoV-2 monoclonal neutralising antibodies, amubarvimab and romlusevimab are obtained from convalesced Covid-19 patients. The company developed these antibodies in partnership with Tsinghua University and the 3rd People’s Hospital of Shenzhen.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 7, 2022
Survey results show 40% of health care leaders believe a lack of communication between prescribers and pharmacists is preventing the successful management of patients’ medications.
Pharmaceutical Technology
JULY 7, 2022
Genetic mutations, both germline and acquired, are behind a large proportion of the most debilitating and sometimes life-threatening human diseases. But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. For many decades, investigators have been working on innovative therapeutic modalities known as cell and gene therapies, which use modified versions of the body’s own cellular and genetic material to treat and potentially cure the
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
JULY 7, 2022
Paxlovid treats COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
European Pharmaceutical Review
JULY 7, 2022
Inadequate investigations and failure to follow standard operating procedures (SOPs) are some of the most common causes for regulatory warning letters in companies, according to Jeanne Moldenhauer, Vice President of Excellent Pharma Consulting. However, she notes that useful information for assessing risks in your facility and preparing for upcoming inspections can be gleaned from other’s warning letters and regulatory inspection observation reports, such as FDA 483.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
JULY 7, 2022
In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. When COVID-19 first emerged, scientists cautioned that developing an effective and safe vaccine could take longer than the commonly estimated figure of a year.
Pharmacy Times
JULY 7, 2022
Trauma informed care has had an impact on the public health spectrum for years, especially with what has happened on a global front.
European Pharmaceutical Review
JULY 7, 2022
Dr Eric Hughes joins Teva with experience in all phases of drug development at global pharmaceutical companies, most recently Boston-based Vertex Pharmaceuticals, which he joined last year. He will be based out of Teva’s US headquarters in Parsippany, New Jersey. . “Eric brings nearly 20 years of leadership roles with a proven track record in a variety of R&D functions for global pharmaceutical companies, and has a successful record of accomplishment fostering productive collaborations with
Pharmacy Times
JULY 7, 2022
The panel of experts explore the contribution provided by pharmacists in the treatment landscape of patients with HR-positive, HER2-negative breast cancer.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
European Pharmaceutical Review
JULY 7, 2022
The WuXi Biologics MFG14 facility has been performing Chemistry, Manufacturing and Controls (CMC) projects since early 2022, and has now started current good manufacturing practice (cGMP) manufacturing of microbial products. It is part of WuXi Biologics’ Integrated Innovation Centre, which was launched in November 2020 to offer products based on microbial fermentation technologies.
Pharmacy Times
JULY 7, 2022
Patient Centered Care is what should be at the heart of a pharmacist's work.
Outsourcing Pharma
JULY 7, 2022
The health care system and analytics company are joining on the ASAP study, a program that constitutes a five-year commitment to advancing cancer solutions.
PharmaVoice
JULY 7, 2022
Precision BioSciences’ CEO discusses the company’s potentially groundbreaking cancer treatment.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
JULY 7, 2022
Brexpiprazole is indicated as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.
PharmaVoice
JULY 7, 2022
Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.
Pharmacy Times
JULY 7, 2022
Sacubitril and Valsartan (Entresto) is indicated to reduce the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure.
Pharmaceutical Technology
JULY 7, 2022
The US Food and Drug Administration (FDA) has granted priority review to Roche’s Biologics License Application (BLA) of Lunsumio (mosunetuzumab) to treat adults with relapsed or refractory (R/R) follicular lymphoma (FL). These patients should have received a minimum of two prior systemic therapies. A CD20xCD3 T-cell engaging bispecific antibody, Lunsumio can act on CD20 present on the B-cell surface and CD3 on the T-cell surface.
Pharmacy Times
JULY 7, 2022
Although treating mental health symptoms is essential, finding the time and energy for more appointments can be challenging for patients with cancer.
Pharmaceutical Technology
JULY 7, 2022
The health concern over COVID-19 in June 2022 decreased from May 2022. It averaged at 23.9%, declining from 25.3% recorded in May 2022, shows the COVID-19 concern index, which is measured by responses to an ongoing poll Verdict launched in March 2020. The poll has been tracking how the concerns over coronavirus have been changing over time. The poll asked how concerned the respondents were about the spread of coronavirus and included five options to choose from - very concerned, slightly concern
pharmaphorum
JULY 7, 2022
New data on Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) has gone a long way towards building confidence in its efficacy – but have introduced a concern about its safety. Updated results from several trials of SRP-9001 (delandistrogene moxeparvovec) revealed a wealth of positives, including functional benefits in patients with the muscle-wasting disease after one to fours years of follow-up, pointing to a durable effect of the gene therapy.
Pharmacy Times
JULY 7, 2022
McKesson ideaShare 2022 is taking place in Washington, DC, from July 7 through 10.
DiversifyRx
JULY 7, 2022
Becoming a sports pharmacy is a great way to boost cash-based revenues along with working with people who are passionate about their health. . Where Sports Pharmacy All Started For Me. I sort of married into sports nutrition and training. While I was an average athlete myself, I married an All-American athlete who had a degree in kinesiology and was a personal trainer.
NF2 BioSolutions
JULY 7, 2022
My name is Nicole Miller, I am 29 years old and suffer from NF2. I got diagnosed when I was 16 years old. I currently work as a nurse in Ophthalmology clinic. I love my job as a nurse and going through many surgeries at a young age is what inspired me to take up my nurse training. The care I received throughout my clinic appointments and surgery was fantastic and knew I wanted to give something back to the NHS and help patients throughout their appointments and stays in hospital.
PharmExec
JULY 7, 2022
In episode 112, Nima Farzan, CEO of Kinnate, who was one of Pharmaceutical Executive’s Emerging Pharma Leaders in 2013, discusses how he’s successfully navigated his career path, from building a foundation in pharma to growing his expertise in biotech.
Pharmaceutical Technology
JULY 7, 2022
It is said that leaders become obsessed with legacy when the curtain begins to fall on their time in power – but leaders don’t write their own history. Although Tony Blair may want to be remembered for public sector reform, peace in Northern Ireland and a reduction in child poverty, any biography of the man will be dominated by the catastrophic consequences of his decision to support the US-led invasion of Iraq.
pharmaphorum
JULY 7, 2022
The rumour that Merck & Co is preparing to make a sizeable offer to buy cancer specialist Seagen won’t go away. The latest report – in the Wall Street Journal – says that “advanced talks” are underway that could lead to a $200-plus per share offer that would value Seagen at a massive $40 billion, $10 billion more than earlier estimates.
Outsourcing Pharma
JULY 7, 2022
The latest indepth report from the AI-centric analytics provider reveals nearly half of US cancer clinical studies enroll no Latino patient participants.
pharmaphorum
JULY 7, 2022
Eradicating cancer is an ambitious goal for oncologists and life science companies around the world. But, with a growing number of cancer treatments entering the market each year and dedicated research efforts driving innovation in the sector, there are positive signs that the industry is on the right track. As this issue’s contributors discuss, by working together pharma companies and healthcare providers can significantly enhance oncology treatment for patients.
Pharmacy Times
JULY 7, 2022
After Bite is indicated for relieving itch from bug bites and other mild irritations.
PharmExec
JULY 7, 2022
Restructuring and ensuring the right talent is in place can help life sciences industry push through latest downward spiral.
Pharmacy Times
JULY 7, 2022
Drs Moore and Dent discuss the impact of oral selective estrogen receptor degraders and modulators in the treatment for HR-positive, HER2-negative breast cancer.
PharmExec
JULY 7, 2022
Amidst lack of funding for women’s health research, industry must collaborate now to advance RMMH.
Pharmaceutical Commerce
JULY 7, 2022
Easing of Omicron restrictions in China played a role, association notes.
Expert insights. Personalized for you.
132 
Let's personalize your content